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Abstract
This secondary analysis of a large, multi-center Blood and Marrow Transplant Clinical Trials 
Network (BMT CTN) randomized trial assessed whether patient-reported outcomes (PROs) and 
socioeconomic status (SES) before hematopoietic stem cell transplantation (HCT) are associated 
with each other and predictive of clinical outcomes including time to hematopoietic recovery, 
acute graft-versus-host disease, hospitalization days, and overall survival (OS) among 646 
allogeneic and autologous HCT recipients. Pre-transplant Cancer and Treatment Distress (CTXD), 
Pittsburgh Sleep Quality Index (PSQI), and mental and physical component scores (MCS and 
PCS) of the SF-36 were correlated with each other and with SES variables. PROs and SES 
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variables were further evaluated as predictors of clinical outcomes, with the PSQI and CTXD 
evaluated as OS predictors (p<.01 considered significant given multiple testing). Lower attained 
education was associated with increased distress (p=.002); lower income was related to worse 
physical functioning (p=.005) and increased distress (p=.008); lack of employment pre-transplant 
was associated with worse physical functioning (p<.01); unmarried status was associated with 
worse sleep (p=.003). In this large heterogeneous cohort of HCT recipients, while PROs and SES 
variables were correlated at baseline, they were not associated with any clinical outcomes. Future 
research should focus on HCT recipients at greater psychosocial disadvantage.
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Introduction
Previous research has shown that baseline patient-reported outcome (PRO) and 
socioeconomic status (SES) measures predict morbidity and mortality following 
hematopoietic cell transplantation (HCT) [1–6]. In contrast to other cancer populations, 
there is minimal published research investigating more proximal clinical events or 
immunologic determinants to suggest candidate biobehavioral mechanisms that might 
explain this relationship [7,8]. Lower levels of optimism and increased anxiety, depression, 
and post-traumatic symptoms in the peri-transplant period are associated with impaired 
white blood cell recovery post-HCT [9–11]. Increased anxiety has also been associated with 
acute graft-versus-host disease (GVHD) [12] and depression has been associated with 
increased inflammation [10]. Finally, absence of spirituality has been associated with greater 
incidence of infection, sepsis, and GVHD [5]. However, these studies have been limited by 
small sample sizes derived from single institutions, retrospective designs, and utilization of a 
variety sampling measures, some of which are non-validated.
Social factors, including SES, confer risk for adverse HCT outcomes [2,13,14]. In other 
cancer populations such as laryngeal and prostate cancer as well as multiple myeloma, SES-
related outcome disparities persist after controlling for differences in access to care and 
health behaviors [15–19]. The mechanisms by which SES and social factors affect outcomes 
are not well defined. Lifestyle and stress associated with low SES can activate 
psychobiological processes that lead to altered neural, endocrine, and immune activation 
[20,21]. A recent study suggests that low SES among unrelated donor HCT recipients is 
associated with increased gene expression patterns representative of chronic adversity [22]. 
This gene profile is predictive of adverse clinical outcomes including increased relapse and 
decreased leukemia-free survival [22].
The purpose of the current study was to evaluate whether PROs and SES factors influence 
morbidity and mortality outcomes among HCT recipients from a large Blood and Marrow 
Transplant Clinical Trials Network (BMT CTN) randomized controlled trial (RCT) [23]. 
The RCT was a 2×2 factorial trial of whether an exercise and/or a stress intervention versus 
usual care for each improved quality of life (QOL) after HCT, in which participants 
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additionally reported survey data prior to HCT and randomization. The primary aim of the 
current study was to examine the relationship between self-reported pre-HCT PROs and SES 
and determine whether these factors were associated with time to hematopoietic recovery. 
Secondary endpoints included acute GVHD (aGVHD), days of life out of the hospital within 
the first 100 days, and overall survival (OS). Specifically, we hypothesized that 1) worse pre-
transplant PROs (including distress, sleep quality, and physical and mental health-related 
QOL) would be associated with adverse SES factors, and 2) better pre-transplant PROs and 
SES would predict decreased time to hematopoietic recovery, decreased incidence and 




The current study was a secondary analysis of BMT CTN protocol 0902, a randomized trial 
of the effect of self-directed exercise and stress management on QOL in HCT recipients 
(ClinicalTrials.gov identifier: NCT01278927, protocol available at www.bmtctn.net) [23]. 
BMT CTN 0902 inclusion criteria were: age ≥18 years, ability to exercise at low to 
moderate intensity (as judged by self-reported ability to walk up 1 flight of stairs), no 
requirement for supplemental oxygen, and autologous or allogeneic transplant to occur 
within six weeks of trial enrollment. Exclusion criteria included orthopedic, neurologic, or 
other problems that prevented safe ambulation or adherence to the protocol; participation in 
another trial with HR-QOL or functional status as a primary endpoint; planned donor 
lymphocyte infusion within 100 days after HCT; planned tandem transplantation; and 
planned anticancer therapies other than tyrosine kinase inhibitors or rituximab within 100 
days after HCT. The 0902 trial was designed to be broadly representative of the general 
HCT population. A protocol review committee appointed by the National Heart, Lung and 
Blood Institute (NHLBI) and all participating transplant center Institutional Review Boards 
or Ethics Committees approved the research protocol. All participants provided written 
informed consent. Eligible participants for this secondary analysis were those from the BMT 
CTN 0902 trial (n=711) who 1) completed the baseline assessment and 2) had Center for 
International Blood and Marrow Transplantation (CIBMTR) pre- and post-transplant 
essential data (TED) forms completed. The final analysis included 310 allogeneic HCT 
recipients and 336 autologous HCT recipients; this final sample of n=646 included patients 
from the original study who were evaluable for multivariate analysis and were not missing 
data on pertinent major variables. The parent study did not show an effect of the intervention 
on the primary outcomes, which were the Physical and Mental Component Summary (PCS 
and MCS) scores of the Medical Outcomes Study Short Form 36 (SF-36) at Day +100 [23]. 
Therefore, we did not anticipate that the intervention would confound our interpretation of 
the prognostic ability of our selected PRO measures to predict clinical outcomes.
Data Collection Instruments
The pre-transplant PRO measures completed at study enrollment included: 1) Cancer and 
Treatment Distress (CTXD) [24,25], a 27-item measure of distress with subscales of 
uncertainty, health burden, family strain, identity, and managing the medical system, as well 
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as distress interference with function; 2) Pittsburgh Sleep Quality Index (PSQI) [26,27], a 7-
item measure of sleep patterns and difficulties such as sleep quality, sleep latency, sleep 
efficiency, and use of sleeping medications; and 3) the SF-36, a 36-item, generic 
multidimensional health-related QOL measure with two summary domains, a physical 
(PCS) and a mental (MCS) component and 8 subscales. The age- and sex-adjusted normal 
population mean for the MCS and PCS is 50 with a standard deviation of 10. A clinically 
meaningful change is considered to be 0.5 standard deviation, or 5 points, with higher scores 
indicating better health-related QOL. For the CTXD and PSQI, higher scores indicate 
greater symptom burden; a CTXD score of >1.1 is indicative of more clinically significant 
distress [28] and a PSQI score of >5 indicates disturbed sleep as adjusted for cancer 
populations [26,27].
Measurements of SES included patient-reported marital status, education level, employment 
status, and household income in the past year. Data collection was performed through the 
BMT CTN and the CIBMTR [23].
Study Outcomes
The primary outcome was time to hematopoietic recovery, defined as time to absolute 
neutrophil count (ANC) > 0.5 × 109/L sustained for three consecutive days for neutrophil 
engraftment, and time to achieve a platelet count of >20 × 109/L independent of platelet 
transfusions for seven consecutive days for platelet engraftment. Secondary outcomes 
included days of life out of the hospital within the first 100 days after HCT and incidence of 
grade II-IV aGVHD (among allogeneic recipients), defined as occurrence (yes vs. no) of 
stage II-IV skin, gastrointestinal or liver abnormalities fulfilling the NIH Consensus criteria 
of aGVHD by 6 months. OS was evaluated as death from any cause, with the time to this 
event defined as the days from HCT to death or last follow-up.
Statistical Analyses
As a first step, linear regression was used to define associations between each pre-transplant 
PRO on SES and clinical variables. Data on all 646 patients were used for fitting these linear 
models.
Next, generalized linear models were used to assess whether PRO and SES measures 
predicted time to neutrophil and platelet engraftment, incidence of aGVHD by day 180 after 
transplant, the number of days out of the hospital in the first 100 days following transplant, 
and OS. The PROs MCS and PCS were not assessed as predictors of OS in these models, as 
these results have been previously reported by Wood et al [29]. Cox proportional hazards 
models were used for the time-to-event outcomes (OS, engraftment), logistic regression was 
used to model the probability of having aGVHD (allogeneic recipients only) by day 180, and 
Poisson and negative binomial regression were used to model the number of days out of 
hospital in the first 100 days. Separate models were constructed for autologous and 
allogeneic HCT patients.
Each of these models adjusted for the four SES factors and other relevant clinical variables. 
Tested clinical variables included age, baseline Karnofsky performance score (KPS; site-
reported, not validated by independent review), alcohol use (yes/no), tobacco use (yes/no), 
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body mass index at baseline, hematopoietic cell transplantation-specific comorbidity index 
(HCT-CI) [30], disease risk index (DRI) [31], prior transplant (yes/no), conditioning 
regimen (myeloablative or not), and graft type (bone marrow, peripheral blood, or cord 
blood). Additional clinical variables analyzed for allogeneic transplants included 
cytomegalovirus (CMV) status, degree of donor/recipient matching, anti-thymocyte globulin 
(ATG)/Campath use, and GVHD prophylaxis. Stepwise variable selection at a 0.05 
significance level was used to identify the clinical variables to include in the final linear and 
generalized linear models. Because they were found to affect the PROs, the four SES 
variables were included in all final models, regardless of their statistical significance.
The correlation between each pair of SES and PRO variables was checked to assess for 
collinearity between predictors. The final assessment of whether the PRO and SES variables 
impacted the outcomes in these models was made using a significance level of 0.01. This 
stricter criterion was chosen to help control the overall false positive rate due to the number 
of main effects and outcomes considered.
For the primary outcome of interest (time to hematopoietic recovery), we assessed the power 
of the Cox model to detect differences of 20% and 10% in engraftment rates of neutrophils 
at day 14 and platelets at day 28 between patients in the low and high categories of PSQI (≤5 
vs. >5) and CTXD (≤1.1 vs. >1.1). The engraftment rates for the low (control) categories 
were assumed to be the estimates obtained from the Aalen-Johansen estimators of 
cumulative incidence at day 14/28 for these groups. Power was assessed separately for each 
of these two factors, for each engraftment rate, and for patients of each transplant type. For 
neutrophil engraftment, we had > 84% power for each factor with both autologous and 
allogeneic patients to detect a 20% difference. For platelet engraftment, we had > 80% 
power in autologous patients and > 90% power in allogeneic patients to detect a 20% 
difference for each factor. For both neutrophil and platelet engraftment, we found that we 
had low power to detect a 10% difference, ranging from 18–34% for each factor with both 
autologous and allogeneic patients.
Testing found no violation of the proportional hazards assumption for any predictor in the 
Cox models. Cause-specific hazard rates were modeled for the engraftment outcomes, which 
are competing risks. All analyses were performed in SAS 9.4 (SAS Institute, Cary, NC).
Results
Participant characteristics
Baseline characteristics for the 646 individuals included in these analyses are shown in 
Tables 1 and 2. Allogeneic transplant-specific variables are included in Table 3. The 
population was evenly divided between autologous and allogeneic HCT recipients. Fifty-
nine percent of recipients had a Karnofsky Performance Status ≥ 90, 80% had an education 
level greater than a high school degree, 53% were not employed at the time of transplant, 
and two-thirds (66%) had an income at the time of HCT of ≥ $50,000. At the time of 
analysis, the median follow-up of survivors was 13 months for autologous transplant 
recipients and 23 months for allogeneic recipients.
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Pre-transplant PROs and SES
Associations between pre-transplant SES and PRO variables are presented in Table 4. Each 
SES variable was found to be associated with at least one PRO at a significance level of 
0.05. The correlation between each pair of SES and PRO variables was fairly weak 
(Spearman correlations < 0.4). Therefore, collinearity between predictors had no appreciable 
impact on the results. Among the entire cohort, lower education was associated with 
increased distress (CTXD, p<0.01). Clinical interpretation of these findings, for example, 
indicate that patients with high school education or less had CTXD scores 0.18 points higher 
on average (almost half a standard deviation) than those with post-high school education, all 
other covariates being equal. Lower pre-transplant household income was significantly 
related to worse physical functioning (PCS, p<0.01) and increased distress (CTXD, p<0.01). 
Lack of employment at the time of transplant was significantly associated with worse 
physical functioning (PCS, p<0.01). Not being married was associated with worse sleep 
(PSQI, p<0.01).
Predictors of Immune Recovery, Overall Survival and Other Clinical Endpoints
None of the pre-transplant SES or PRO variables assessed in this study were significantly 
associated with the primary (neutrophil or platelet engraftment; see Table 5) or secondary 
(aGVHD, days of life out of the hospital by day 100, or OS (data not shown)) endpoints 
among either autologous or allogeneic HCT recipients at the p<0.01 significance level. 
Neutrophil engraftment at day 14 and platelet engraftment at day 28 was 89.0% and 79.8% 
for autologous recipients and 53.9% and 78.0% for allogeneic recipients, respectively. 
Effects of physical and mental functioning on OS have been previously reported [29]. 
Assignment to exercise or stress intervention was not predictive of any clinical outcomes 
assessed.
Discussion
These data demonstrate that low SES is associated with worse pre-transplant physical 
functioning as well as increased distress and poor sleep quality. Neither SES nor the pre-
transplant PROs physical and mental functioning, distress, and sleep quality were associated 
with the primary outcome of hematopoietic recovery after HCT. This is the largest HCT 
cohort to date evaluating SES and PROs as predictors of hematopoietic recovery. These 
factors were also not significantly associated with the secondary clinical outcomes assessed, 
including aGVHD and days of life out of the hospital by day 100; distress and sleep quality 
were not associated with OS.
In other studies, social disparities were found to contribute additional independent risk for 
people with cancer [4,7,8,32–35], with patients of lower SES at risk of increased morbidity 
and mortality [36–42]. In the HCT setting, low SES, independent of race, has a negative 
impact on unrelated and related donor outcomes, including worse OS and higher transplant-
related mortality (TRM) [14,43]. The current findings support the recent CDC survey data 
that serious psychological distress is a significant health issue, particularly among 
individuals of low SES [44]. They also corroborate previous research demonstrating that low 
SES among allogeneic HCT recipients is associated with increased expression of the 
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“conserved transcriptional response to adversity” (CTRA), a profile of 53 genes that are up-
regulated under conditions of chronic stress and associated with worse clinical outcomes 
[22].
The present null findings are somewhat unexpected given prior evidence from other HCT 
populations suggesting an association between pre-transplant SES and PRO variables and 
clinical outcomes [4,5,9,11,12,22,29,35,45]. Recently, Wood et al. [29] identified that the 
pre-transplant PCS scale independently predicted overall mortality in the same cohort of 
autologous and allogeneic HCT recipients used in the present study. It may be that physical 
status, and not perceived distress or mental health-related QOL, as evaluated here, is a more 
sensitive PRO for predicting clinical outcomes. In the current study, PCS was associated 
with lack of employment at time of transplant. While multivariate modeling indicated that 
the covariates KPS (p<0.001) and HCT-CI (p<0.01), but not DRI, were significant when 
SES factors were assessed in relation to PCS (complete data not shown), it is possible this 
relationship is reflective of longer disease duration prior to transplant, though this was not 
directly assessed.
The current findings support an association between unmarried status and poorer sleep 
quality, underscoring the importance of assessing close relationships when evaluating sleep 
and health [46]. Prior research indicates that married older adults have better actigraph-
estimated sleep [47] and married women with metastatic breast cancer have better sleep 
quality [48]. It may be that HCT recipients who are unmarried are more likely to be sleeping 
alone; accommodating a caretaker in patients’ homes post-transplant could prove to be 
disruptive to sleep hygiene. This relationship should be further explored among HCT 
recipients in future studies.
We performed additional post hoc analyses evaluating the relationship between pre-
transplant factors and outcomes in only the groups with PRO scores >1 SD from the mean, 
since these were the patients reporting the greatest psychosocial and functional distress (data 
not shown); no significant relationship was identified. It is possible that the significant 
physical and immunological perturbation inherent in the HCT process and the underlying 
heterogeneity of the study population obfuscate any potential relationship between 
emotional status and immunologic determinants that could impact outcomes. In particular, 
the powerful immunosuppressive agents used to prevent and treat GVHD in allogeneic 
recipients may overshadow any influence of SES and PRO factors on immune function, 
although there is prior evidence to suggest otherwise [4,45]. Given the observation of this 
relationship in smaller cohorts, it seems less plausible that true associations would not be 
evident in our significantly larger cohort, unless there was not sufficient adjustment for other 
transplant-, disease-, and patient-related factors in prior studies. Incorporating infused 
number of CD34+ cells could help confirm the presence of these true associations by 
assessing whether engraftment in the present cohort was what would be expected; however, 
rates of missing data on cell dose were too high to evaluate this conclusively. Investigational 
analyses (not reported) suggest that this relationship was as would be expected in the present 
cohort and that cell dose did not affect the relationships between PROs or SES and 
outcomes. This should be further evaluated in future studies. While time to hematopoietic 
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recovery was assessed as a continuous variable in both the current and prior studies, analytic 
strategies employed varied, which can result in different outcomes.
Alternatively, it is possible that the selection bias with this particular cohort who agreed to 
participate in an effort-based intervention resulted in an inherently less vulnerable group 
with better PRO measures and SES than previous smaller cohorts. Indeed, the mean mental 
functioning score in the current sample is representative of a general normative adult 
population. This is in contrast to other literature indicating high levels of distress in HCT 
patients both prior to and following HCT [24,49,50]. Further, distress levels are lower in the 
present cohort (median CTXD = 1.0; Interquartile range (IQR) = 0.7 – 1.5 in autologous 
recipients) as compared to both the initial multicenter study establishing CTXD 
psychometric validity (median CTXD = 1.2; SD = 0.5) [28] and the population evaluated by 
McGregor et al. demonstrating distress modulating post-transplant white blood cell recovery 
(median CTXD = 1.2; IQR = 0.8 – 1.6 in autologous recipients) [9]. Finally, SES may not 
have been associated with OS or other outcomes in this study because the present sample 
was not necessarily representative of individuals from lower SES categories who may be 
more vulnerable to adverse clinical outcomes; approximately 80% of the present sample had 
education beyond high school, which is substantially greater than the 65% national average 
[51]. Future studies could assess whether this is reflective of clinical trial participation or 
high SES in general of HCT patients. Although strengths of this study include its large 
cohort size, enrollment of transplant recipients from over twenty centers, and a range of 
potential demographic and psychosocial stressors, a limitation is our lack of knowledge of 
who declined participation or was not approached for study consent. Taken together, a 
possible limitation is that the present sample may not fully represent the distribution of 
stressors inherent in the general HCT population.
In conclusion, this study demonstrates limited support for SES and PROs as risk 
prognosticators for hematopoietic recovery, aGVHD incidence, days of life out of the 
hospital, or survival. Future research may evaluate more sensitive biological measures - such 
as gene expression - in addition to clinical outcomes, and may focus on HCT recipient 
subsets reporting worse PROs at baseline, indicating perhaps greater vulnerability to adverse 
outcomes.
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• PRO and SES variables were correlated pre-transplant.
• Neither PRO nor SES variables were significantly associated with 
clinical outcomes.
• Future research should focus on HCT patients at greater psychosocial 
disadvantage.
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Table 1
Baseline patient demographic characteristics of secondary analysis participants
Variable Autologous Allogeneic
Number of enrolled patients 336 310
Number of centers 23 19
Age at transplant, years,
median(range)
59 (19–76) 54 (20–75)
Age at transplant, n (%)
    ≤ 40 29 (9) 58 (19)
    40-<65 211 (63) 205 (66)
    ≥ 65 96 (29) 47 (15)
Ethnicity, n (%)
    Hispanic 20 (6) 15 (5)
    Non-Hispanic 316 (94) 295 (95)
Race, n (%)
    American Indian/Alaska 0 1 (<1)
Native
    Asian 5 (1) 5 (2)
    Hawaiian/Pacific Islander 0 3 (<1)
    Black or African American 44 (13) 10 (3)
    White 285 (85) 284 (92)
    More than one race 1 (<1) 5 (2)
    Other/unknown 1 (<1) 2 (<1)
Recipient sex, n (%)
    Male 193 (57) 173 (56)
    Female 143 (43) 137 (44)
Marital status, n (%)
    Married/Living with partner 243 (72) 242 (78)
    Single, never married 32 (10) 39 (13)
    Separated, Divorced 47 (14) 20 (6)
    Widowed 10 (3) 7 (2)
    Missing 4 (1) 2 (<1)
Education, n (%)
    <=High School 68 (20) 60 (19)
    College graduate 197 (59) 191 (62)
    Postgraduate 69 (21) 58 (19)
    Missing 2 (<1) 1 (<1)
Employment status, n (%)
    No 184 (55) 160 (52)
    Yes 152 (45) 150 (48)
Income, n (%)
    Under $15,000 16 (5) 21 (7)
    $15,000–$24,999 23 (7) 21 (7)
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Variable Autologous Allogeneic
    $25,000–$49,999 71 (21) 52 (17)
    $50,000–$74,999 71 (21) 64 (21)
    $75,000–$99,999 48 (14) 40 (13)
    $100,000 or above 87 (26) 92 (30)
    Missing 20 (6) 20 (6)
Karnofsky score, %, n (%)
    ≥ 90 192 (57) 190 (61)
    70 – 80 139 (41) 113 (36)
    50 – 60 5 (1) 5 (2)
    Missing/Not done 0 2 (<1)
Tobacco use, n (%)
    No 306 (91) 288 (93)
    Yes 28 (8) 20 (6)
    Unknown 2 (<1) 2 (<1)
Alcohol use, n (%)
    No 189 (56) 190 (61)
    Yes 146 (43) 120 (39)
    Unknown 1 (<1) 0
BMI, median (range) 28.31 (16.10–52.27) 27.65 (17.06–55.55)
BMI, n(%)
    < 25 78 (23) 88 (28)
    25– 29.9 125 (37) 112 (36)
    ≥ 30 133 (40) 110 (35)
Baseline intervention, n (%)
    No 2 (<1) 4 (1)
    Yes 333 (99) 306 (99)
    Unknown 1 (<1) 0
Baseline SF36 Physical Component
Score
    Median 43 44
    IQR 34–49 36–51
    Range 13–64 13–65
Baseline SF36 Mental Component
Score
    Median 52 52
    IQR 46–58 43–57
    Range 18–74 7–68
PSQI at baseline
    Median 4.0 4.0
    IQR 2.0–7.0 2.0–6.0
    Range 0.0–14.0 0.0–15.0
    Missing 8 11
CTXD at baseline
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Variable Autologous Allogeneic
    Median 1.0 1.1
    IQR 0.7–1.5 0.8–1.6
    Range 0.0–2.8 0.0–3.0
Exercise Intervention, n (%)
    No 165 (49.1) 150 (48.4)
    Yes 171 (50.9) 160 (51.6)
Stress Intervention, n (%)
    No 167 (49.7) 157 (50.6)
    Yes 169 (50.3) 153 (49.4)
Median follow-up of survivors (range),
months
13 (2–36) 23 (6–35)
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Table 2
Baseline disease related characteristics of secondary analysis participants
Variable Autologous Allogeneic
Disease, n (%)
    AML/ALL 0 163 (53)
    CML 0 12 (4)
    MDS/MPS 0 44 (14)
    MM/PCD 172 (51) 14 (5)
    Lymphoma 164 (49) 57 (18)
    CLL/SLL 0 20 (6)
Disease status, n (%)
  AML/ALL
    Early 116 (71)
    Intermediate 30 (18)
    Late 17 (10)
  CML
    Early 6 (50)
    Intermediate 4 (33)
    Late 2 (17)
  MDS/MPS
    Early 21 (48)
    Intermediate 9 (20)
    Late 14 (32)
  MM/PCD
    Early 24 (14) 3 (21)
    Intermediate 135 (78) 8 (57)
    Late 13 (8) 3 (21)
  Lymphoma
    Early 57 (35) 3 (5)
    Intermediate 69 (42) 28 (49)
    Late 38 (23) 25 (44)
    Missing 0 1 (2)
  CLL/SLL
    Early 5 (25)
    Intermediate 7 (35)
    Late 8 (40)
Hematopoietic cell transplantation-
specific comorbidity index (HCT-CI), n
(%)
    0 109 (32) 108 (35)
    1–2 107 (32) 93 (30)
    3+ 115 (34) 106 (34)
    Missing 5 (1) 3 (<1)
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Variable Autologous Allogeneic
Disease risk index, n (%)
    Low 64 (19) 54 (17)
    Intermediate 224 (67) 144 (46)
    High 22 (7) 52 (17)
    Very high 14 (4) 11 (4)
    Missing 12 (4) 49 (16)
EBMT score, n (%)
    1 6 (2) 58 (19)
    3 72 (21) 73 (24)
    4 220 (65) 137 (44)
    ≥5 38 (11) 42 (14)
Prior transplant, n (%)
    No 318 (95) 267 (86)
    Yes 18 (5) 43 (14)
Prior cytotoxic chemotherapy, n (%)
    No 32 (10) 43 (14)
    Yes 281 (84) 250 (81)
    Unknown 23 (7) 17 (5)
Patient CMV status, n (%)
    Positive 196 (58) 165 (53)
    Negative 139 (41) 145 (47)
    Missing 1 (<1) 0
In allogeneic, conditioning intensity, n
(%)
    MA 135 (44)
    RIC/NMA 175 (56)
Graft type, n (%)
    BM 0 39 (13)
    PB 336 246 (79)
    Double CB 0 25 (8)
Disease/Disease risk index
  AML/ALL
    Low 20 (12)
    Intermediate 68 (42)
    High 31 (19)
    TBD 44 (27)
  CML
    Low 8 (67)
    Intermediate 2 (17)
    TBD 2 (17)
  MDS/MPS
    Low 5 (11)
    Intermediate 30 (68)
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    High 9 (20)
  MM/PCD
    Intermediate 158 (92) 11 (79)
    High 14 (8) 3 (21)
  Lymphoma
    Low 64 (39) 12 (21)
    Intermediate 66 (40) 23 (40)
    High 8 (5) 9 (16)
    Very high 14 (9) 10 (18)
    TBD 12 (7) 3 (5)
  CLL/SLL
    Low 9 (45)
    Intermediate 10 (50)
    Very high 1 (5)
Abbreviations for Tables 1 and 2: BMI = Body Mass Index; PSQI = Pittsburgh Sleep Quality Index; CTXD = Cancer and Treatment Distress scale; 
LSI = Leisure Score Index; SRC = Stress Reduction Checklist; AML = Acute Myeloid Leukemia; ALL = Acute Lymphoblastic Leukemia; CML = 
Chronic Myeloid Leukemia; MDS = Myelodysplastic Syndrome; MPS = Myeloproliferative Syndrome; MM = Multiple Myeloma; PCD = Plasma 
Cell Dyscrasia; CLL = Chronic Lymphocytic Leukemia; SLL = Small Lymphocytic Lymphoma; EBMT = European Group for Blood and Marrow 
Transplantation; CMV = Cytomegalovirus; MA = myeloablative; RIC = Reduced Intensity Conditioning; NMA = Non-myeloablative; BM = Bone 
Marrow; PB = Peripheral Blood; CB = Cord Blood; IQR = Interquartile Range

















Number of enrolled patients 310
Number of centers 19
Donor type, n (%)
  HLA identical sibling 106 (34)
  Other Related 20 (6)
  Unrelated 159 (51)
  CB 25 (8)
Donor match, n (%)
  HLA identical sibling 27 (79)
  Other Related
    Partially matched 1 (3)
    Mismatched 6 (18)
  Unrelated
    Well matched 16 (43)
    Partially matched 21 (57)
Donor sex, n (%)
  Male 184 (59)
  Female 126 (41)
Recipient/Donor CMV, n (%)
  +/+ 75 (24)
  +/− 87 (28)
  −/+ 29 (9)
  −/− 106 (34)
  Missing 13 (4)
GVHD prophylaxis, n (%)
  CD34 selection+/− post-tx immune 10 (3)
  Cyclophosphamide 2 (<1)
  FK+MMF+others, FK+/−others 42 (14)
  FK+MTX 42 (14)
  CSA+MMF+others,CSA+/−others 54 (17)
  Other GVHD prophylaxisa 4 (1)
  Missing due to no CRF forms 156 (50)
a
Other GVHD prophylaxis: mtx + other, not specified (n=3), other, not specified (n=1)

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 December 01.
